EP Patent

EP1092434A1 — Novel composition containing lansoprazole and process for its preparation

Assigned to Ratiopharm GmbH · Expires 2001-04-18 · 25y expired

What this patent protects

The invention provides a composition exempt of alkaline-reacting compounds comprising : (a) - a core containing lansoprazole, said core being constituted of nuclei and said active ingredient mixed together and then compressed together, and said active principle not being in th…

USPTO Abstract

The invention provides a composition exempt of alkaline-reacting compounds comprising : (a) - a core containing lansoprazole, said core being constituted of nuclei and said active ingredient mixed together and then compressed together, and said active principle not being in the form of an alkaline salt ; (b) - an intermediate layer; and (c) - an enteric layer. The invention also provides a process for its preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP1092434A1
Jurisdiction
EP
Classification
—
Expires
2001-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Ratiopharm GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.